Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson Sells 10,471 Shares of Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson sold 10,471 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the completion of the transaction, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at approximately $2,930,498.14. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Alkermes Stock Performance

Shares of ALKS stock opened at $29.29 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The stock has a market cap of $4.74 billion, a PE ratio of 15.02, a price-to-earnings-growth ratio of 0.88 and a beta of 0.47. The business has a 50-day simple moving average of $27.64 and a 200-day simple moving average of $26.01. Alkermes plc has a 52-week low of $22.06 and a 52-week high of $32.88.

Analyst Ratings Changes

A number of brokerages have commented on ALKS. JPMorgan Chase & Co. reduced their target price on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and increased their target price for the company from $25.00 to $36.00 in a research report on Tuesday. The Goldman Sachs Group reduced their price target on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Robert W. Baird raised their price objective on Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Finally, StockNews.com upgraded Alkermes from a “hold” rating to a “buy” rating in a research note on Sunday, July 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alkermes has an average rating of “Moderate Buy” and a consensus price target of $35.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ALKS. V Square Quantitative Management LLC acquired a new stake in Alkermes in the 3rd quarter valued at about $29,000. Signaturefd LLC raised its stake in shares of Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after acquiring an additional 480 shares during the period. Hexagon Capital Partners LLC raised its holdings in shares of Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after buying an additional 1,498 shares during the period. GAMMA Investing LLC lifted its position in shares of Alkermes by 44.4% during the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares in the last quarter. Finally, Archer Investment Corp lifted its holdings in Alkermes by 28.6% during the 3rd quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after buying an additional 1,000 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.